Information about Peramivir
Zanamivir is an inhibitor of the influenza neuramidase enzyme and is given by inhalation as therapy and prophylaxis against influenza A and B. Zanamivir has not been associated with clinically apparent liver injury, at least when given by inhalation.
Mechanism of action of Peramivir
Zanamivir (za nam' i vir) is a sialic acid analogue and a potent inhibitor of the neuraminidase of influenza viruses. Inhibition of this enzyme causes a decrease in viral replication, probably as a result of interference with particle formation and release. Zanamivir is active against both influenza A and B viruses, but has no activity against other common upper respiratory tract viruses. In addition, resistance to zanamivir can develop rapidly.
Clinical use of Peramivir
Zanamivir is indicated for therapy or post-exposure prevention of influenza A or B. Zanamivir was approved in the United States in 1999 and is frequently used during influenza outbreaks. Zanamivir is available as a powder for inhalation (5 mg/blister pack) under the brand name of Relenza.
Dosage and administration for Peramivir
The recommended dose for therapy in adults is 2 oral inhalations of 5 mg each, twice daily for 5 days; the usual prophylactic regimen is 10 mg once daily for 10 days, starting within 2 days of close contact with an infected person or for 28 days in a community setting. Side effects are uncommon and include mild nausea, dizziness, headache, cough, nasal and throat irritation and bronchospasm. Drugs for HIV Infection, in the Subclass Antiretroviral Agents
- Nonnucleoside Reverse Transcriptase Inhibitors (HIV)
- Nucleoside Analogues (HIV)
- Protease Inhibitors (HIV)
HCV NS5A Inhibitors
HCV NS5B Inhibitors (Polymerase inhibitors)
- Asunaprevir, Boceprevir, Glecaprevir, Grazoprevir, Paritaprevir, Simeprevir, Telaprevir, Voxilaprevir
Drugs for Herpes Virus
Drugs for Influenza